Inhalable Biologics Market Trends for 2026

The global inhalable biologics market size was estimated at USD 4.51 billion in 2025 and is predicted to increase from USD 5.3 billion in 2026 to approximately USD 22.87 billion by 2035, expanding at a CAGR of 17.64% from 2026 to 2035.

The growing chronic diseases and the demand for target-specific products are increasing the use of inhalable biologics. The growing technological advancements, expanding healthcare, and new launches are also promoting the market growth.

Key Takeaways

• Inhalable biologics market to crossed USD 5.3 billion by 2026.
• Market projected at USD 22.87 billion by 2035.
• CAGR of 17.64% expected in between 2026 to 2035.
• North America dominated the global inhalable biologics market by 40% share in 2025.
• Asia Pacific is expected to be the fastest-growing region between 2026 and 2035.
• By type, the peptides and proteins segment dominated the market in 2025.
• By type, the RNAi-based therapeutics segment is expected to be the fastest growing during the forecast period.
• By application type, the respiratory diseases segment dominated the market in 2025.
• By application type, the diabetes segment is expected to be the fastest growing during the forecast period.
• By dosage form type, the dry powder inhalers segment dominated the inhalable biologics market in 2025.
• By dosage form type, the nebulizers segment is expected to be the fastest growing during the forecast period.
• By distribution channel type, the hospital pharmacies segment dominated the market in 2025.
• By distribution channel type, the retail pharmacies segment is expected to be the fastest growing during the forecast period.

What are the Inhalable Biologics?

The inhalable biologics market is fueled by the growing respiratory conditions and shift towards patient-centric, non-invasive delivery platforms. The inhalable biologics encompass the biological drugs delivered through the respiratory tract offering local or systemic action. They are being utilized for the treatment of various respiratory diseases, genetic diseases, diabetes, and metabolic disorders.

Inhalable biologics include proteins, peptides, monoclonal antibodies, vaccines, nucleic acids, and other large biological molecules formulated for pulmonary delivery. Advanced technologies such as dry powder inhalers, nebulizers, and metered-dose inhalers improve drug stability and targeted delivery. This approach helps reduce injections, enhances patient comfort, and supports better treatment adherence. Researchers are also developing advanced formulations that improve absorption, extend drug action, and reduce dosing frequency for chronic diseases and long-term therapies.

The market is supported by continuous progress in biotechnology, inhalation devices, and formulation science. Pharmaceutical companies are investing in innovative inhaled biologics for respiratory and systemic diseases. Increasing clinical research and strategic partnerships are accelerating product development. Regulatory support for innovative drug delivery technologies is also encouraging innovation. Growing demand for personalized medicine, home-based treatment, and self-administration is expected to create new opportunities, making inhalable biologics an important area of future pharmaceutical development and healthcare innovation.

AI Technological Shifts in the Inhalable Biologics Market

In the development of inhalable biologics, AI is being utilized for target identification and product optimization. The particle size, shape, density, pharmacokinetics, and device performance are also optimized using AI, which also predicts the stability and adverse effects of the biologics. Moreover, it is also being used in the development of smart inhalers, tracking usage patterns, lung function, and treatment effectiveness.

What are the Trends & Future Outlook of the Inhalable Biologics Market?

Advancements In Biologic Therapies

Due to growing chronic diseases, the demand for their treatment options is increasing, which is driving the development of next-generation inhalable biologics, offering target-specific action for various diseases.

Blooming Delivery Systems

To enhance the delivery, stability, and absorption of the biologics through the nasal route, a wide range of delivery systems, such as solid powders, lipid carriers, and nanoparticle carriers, are being developed.

Shift Towards Home Care

There is a rise in the demand for self-administered inhalable biologics, due to growing home-based care for the long-term management of chronic disease, which is increasing the development of new portable nebulizers and the integration of dosage tracking technologies.

Quick Facts Table

Segmental Insights

By Type Insights

Why Did the Peptides and Proteins Segment Dominate in the Inhalable Biologics Market in 2025?

The peptides and proteins segment held the dominating share of the market in 2025, due to their enhanced potency. They also offered low doses and rapid absorption, which increased their use. Moreover, their poor oral availability and non-invasive approaches also increased the use of inhalable solutions.

RNAi-based Therapeutics

The RNAi-based therapeutics segment is expected to show the highest growth during the upcoming years, due to their target-specific action. They also provide long-term effectiveness, reducing the dosing frequencies. The growing advancements in the formulations and delivery systems are also increasing their adoption rates.

By Application Insights

How Respiratory Diseases Segment dominate the Inhalable Biologics Market in 2025?

The respiratory diseases segment led the market in 2025, as the inhalable biologics offer direct delivery to the lungs. The faster onset of action and low systemic side effects also encouraged their use. The growth in respiratory diseases also increased their use as a non-invasive approach, which enhanced patient adherence to the treatment.

Diabetes

The diabetes segment is expected to show the fastest growth rate during the upcoming years, due to its growing incidence rates. This is increasing the demand for insulin therapies with longer duration of action, promoting the use of their inhalational solutions. Their growing approvals and enhanced patient comfort are also increasing their acceptance rates.

By Dosage Form Insights

Which Dosage Form Type Segment Held the Dominating Share of the Inhalable Biologics Market in 2025?

The dry powder inhalers segment held the dominating share of the market in 2025, due to their enhanced stability. Their portability, non-propellant, and ease of use increased their acceptance rates for the management of chronic disease conditions. Moreover, their acute dosing and widespread availability also increased their use.

Nebulizers

The nebulizers segment is expected to show the highest growth during the predicted time, due to their ability to deliver high doses of biologics. They are also being used in a wide range of age groups, as they deliver the drug during normal breathing. This is driving the development of new portable nebulizers.

By Distribution Channel Insights

What Made Hospital Pharmacies the Dominant Segment in the Inhalable Biologics Market in 2025?

The hospital pharmacies segment led the market in 2025, as they offered medical supervision. Their effective handling and advanced storage facilities also increased the purchase volume of the inhalable biologics. Moreover, the insurance policies also attracted the patients and increased their use during the severe cases.

Retail Pharmacies

The retail pharmacies segment is expected to show the fastest growth rate during the predicted time, due to their widespread availability and presence of various products. The growing shift towards home care and increasing health awareness are also increasing their use for the long-term management of chronic diseases.

Regional Insights

Advanced Healthcare Drives North America

North America dominated the inhalable biologics market by 40% share in 2025, due to the presence of advanced healthcare infrastructure, which increased the adoption rates of the inhalable biologics. The growth in the R&D activities focused on innovative therapies and increased respiratory diseases, also increased their use, where the high healthcare investments also contributed to the market growth.

U.S. Market Trends

The U.S. consists of advanced healthcare and R&D infrastructure, which is increasing the use and innovations of inhalable biologics, where the reimbursement policies are also increasing their use. There is a rise in the innovations of inhalational insulin and monoclonal antibodies, where the growing regulatory approvals are also increasing their advancements.

Canada Market Trends

Canada's inhalable biologics market is growing with increasing cases of respiratory diseases and strong investment in biotechnology research. Academic institutions and pharmaceutical companies are developing advanced inhaled biologic therapies. Government support for healthcare innovation encourages clinical research. Demand for non-invasive drug delivery is rising among patients and healthcare providers. Growing adoption of personalized medicine and home-based treatment will continue creating opportunities for future market expansion.

Growing Disease Burden Boosts Asia Pacific

Asia Pacific is expected to host the fastest-growing inhalable biologics market by 24% share during the forecast period, due to growing respiratory diseases and diabetes cases. The increasing health awareness is also increasing the use of inhalable biologics, where the expanding healthcare is also increasing their innovations, which are backed by investment from various sources, enhancing the market growth.

China Market Trends

The expanding healthcare is increasing the adoption of inhalable biologics in China to tackle the growing chronic respiratory disease and diabetes. The growing health awareness is also increasing their use, where the government support and investments are also increasing their advancements.

India Market Trends

India's inhalable biologics market is expanding because of rising respiratory disease burden, improving healthcare infrastructure, and increasing biotechnology investments. Pharmaceutical companies are focusing on innovative inhaled therapies for chronic diseases. Government initiatives supporting domestic biopharmaceutical manufacturing encourage product development. Growing awareness of non-invasive treatment options is increasing patient acceptance. Continuous clinical research, expanding healthcare access, and affordable drug development will support future market growth across the country.

Europe Driven by High Biologics Adoption

Europe is expected to grow significantly in the inhalable biologics market by 28% share during the forecast period, due to high adoption of biologics, which increased their innovations, driving the use of inhalable biologics. The presence of advanced healthcare and growth in chronic diseases is also increasing their use, where growth in home-based healthcare is also increasing their acceptance rates, promoting market growth.

UK Market Trends

The presence of advanced healthcare systems is increasing the use of inhalable biologics in the UK. The growing cases of asthma and cystic fibrosis are also increasing their use, where the robust R&D infrastructure is also driving new opportunities in the development of novel biologics and drug delivery devices.

Germany Market Trends

Germany's inhalable biologics market is growing steadily with strong pharmaceutical research, advanced healthcare infrastructure, and increasing demand for innovative respiratory therapies. Biotechnology companies are investing in inhaled biologic formulations and advanced drug delivery technologies. Research collaborations between industry and academic institutions support product innovation. Rising adoption of personalized medicine and non-invasive treatments is driving demand. Continuous investments in clinical research will strengthen future market development.

Inhalable Biologics Market Value Chain Analysis

R&D

• The R&D of the inhalable biologics focuses on the development of advanced particles and technosphere dry powder technology.
• Key players: AstraZeneca, GlaxoSmithKline, MannKind Corporation.

Clinical Trials and Regulatory Approvals

• The device-drug deposition patterns, bioequivalence of inhalable biologics, and local lung mucosal safety are evaluated in the clinical trials and regulatory approvals of the inhalable biologics.
• Key players: AstraZeneca, GlaxoSmithKline, MannKind Corporation.

Patient Support and Services

• The digital health platforms and connected smart inhalers are provides for the patient support and services for inhalable biologics.
• Key players: AstraZeneca, GlaxoSmithKline, Teva Pharmaceutical Industries.

Who are the Inhalable Biologics Market Top Vendors and What are Their Offerings?

Latest Announcement by the Industry Leader

In January 2025, “Lonza is a world leader in bioavailability enhancement and renowned for its spray-drying capabilities of biologics. Combined with Iconovo’s unique nasal inhaler, we expect the result to be an unprecedented patient-friendly product, and we hope that this cooperation will lead to a fruitful, long-term collaboration that goes beyond this specific project,” said Johan Wäborg, CEO, Iconovo, in a company press release.

SWOT Analysis

Strengths

• The inhalable biologics offer non-invasive drug delivery, which increases the patient's comfort and adherence to the treatment.
• Their ability to deliver drugs to the lungs is also increasing their use in the treatment of various respiratory diseases.
• The rapid onset of action and low risk of systemic side effects are also increasing their adoption rates.
• Moreover, they are preferred to deliver drug products with a risk of degradation in the GI tract.

Weaknesses

• The stability problems related to the biologics act as the major weakness in the inhalable biologics market, reducing their innovations.
• The limited absorption of certain drugs through the lungs also reduces the use of these formulations.

Opportunities

• The growing incidence of respiratory disease and diabetes is increasing the use of inhalable biologics for their effective management and treatment.
• The growing R&D activities focused on biologics development are also increasing new opportunities for their inhalable products.
• Increasing technological advancements and combination therapies are also driving their innovations.
• Shift towards home-based care is also increasing the adoption rates of the inhalable biologics.

Threats

• The inhalable biologics require high-quality raw materials and specialized delivery devices, which increases the cost associated with their development, limiting their use.
• The regulatory hurdles for biologics as well as inhalation devices slow down their approvals and innovations.

What are the Recent Developments in the Inhalable Biologics Market?

• In June 2025, Quattrii, the ‘first ever’ dry powder inhaler (DPI) engine, delivering large volumes of biologic and mRNA molecules, with approximate 70% of the drug in a single inhalation, was launched by Cambridge Healthcare Innovations (CHI).
• In March 2025, the phase-2 clinical trial of the next-generation, inhaled COVID-19 vaccine was announced to have been initiated by McMaster University, where they will identify the safety of the vaccine in a broad study group.

Segments Covered in the Report

By Type

• Peptides and Proteins
• Vaccines
• Monoclonal Antibodies
• RNAi-based Therapeutics
• Others

By Application

• Respiratory diseases
• COPD
• Asthma
• Cystic Fibrosis
• COVID-19
• Others
• Diabetes
• Cancer
• Others

By Dosage Form

• Dry Powder Inhalers
• Metered Dose Inhalers
• Nebulizers
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
  • Rest of North America
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Europe
  • Western Europe
    • Germany
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal
    • Belgium
    • Ireland
    • UK
    • Iceland
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe
    • Austria
    • Russia & Belarus
    • Türkiye
    • Albania
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • Taiwan
  • India
  • Japan
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea
  • Rest of APAC
• MEA
  • GCC Countries
    • Saudi Arabia
    • United Arab Emirates (UAE)
    • Qatar
    • Kuwait
    • Oman
    • Bahrain
  • South Africa
  • Egypt
  • Rest of MEA